Abstract
In this issue of Blood, Dimier et al, for the first time, quantitate the relationship between minimal residual disease (MRD) negativity and progression-free survival (PFS) in patients receiving chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia (CLL), establishing its validity as a surrogate marker for PFS.1
| Original language | English (US) |
|---|---|
| Pages (from-to) | 943-944 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 131 |
| Issue number | 9 |
| DOIs | |
| State | Published - Mar 1 2018 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology